RxDoctor Payments Data

Bill Davis, MD

Neurology · New Braunfels, TXNPI 1154352557

Payments from drug & device makers

$793in general payments, 2019–2025

Across 36 payments — averaging $22.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$213
  • Medtronic$206
  • Abbott$139
  • Novo Nordisk$75
  • Livanova USA, Inc.$26
  • Boston Scientific$26
  • plus $108 from 6 others

What the payments were for

  • Speaking & faculty fees$111%
  • Food & beverage$78299%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$793 in reported general payments places this provider in the 35th percentile of 1,246 neurology providers in Texas.

See all neurology providers in Texas

Medicare billing

Part B allowed, 2024
$167,686
Medicare patients
638
Services billed
8,303

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate17$83,715
Aimovig AutoinjectorErenumab-Aooe62$64,079
RytaryCarbidopa/Levodopa17$31,552
RexultiBrexpiprazole16$28,971
Emgality PenGalcanezumab-Gnlm36$28,186
Carbidopa-LevodopaCarbidopa/Levodopa344$14,897
Depakote ErDivalproex Sodium15$11,106
Gabapentin399$10,036
Emgality SyringeGalcanezumab-Gnlm12$9,273
Memantine Hcl360$9,205
Levetiracetam128$6,133
Donepezil Hcl448$4,904
Primidone109$4,087
Carbidopa-Levodopa ErCarbidopa/Levodopa33$3,970
Ropinirole Hcl83$3,830

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$24$83,71517 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 1,246 neurology providers in Texas.

Other neurology in New Braunfels

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →